Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$1.54M$1.54M+49.4% vs Q2 2017 Net Income-$1.46M-$1.46MN/M vs Q2 2017 EPS Diluted-$0.03-$0.03N/M vs Q2 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,523,000N/M Free Cash Flowderived-$1,619,000N/M Margins · derivedGross margin34.6%+34.7 pt vs Q2 2017
Operating margin-95.6%+48.3 pt vs Q2 2017
Net margin-95.2%+45.8 pt vs Q2 2017
ended Dec 31, 2017 · filed Feb 9, 2018 · 40 d after period end